AGAMREE DIN 02561506
Health Canada record
| Active ingredient(s) | VAMOROLONE 40 MG |
|---|---|
| Dosage form | Suspension |
| Route | Oral |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | H02AB18 VAMOROLONE |
| Original market date | 24-Apr-2026 |
| Current status date | 24-Apr-2026 |
| Source | Health Canada DPD |
Establishment licence of the holder
KYE Pharmaceuticals Inc. — licence 3-002615, currently licensed, last inspection rating C (2025-09-08).
No Canadian shortage report is currently matched to this DIN.
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 36073 | 2025-09-29 | New Drug Submission (NDS) |
International API supply for VAMOROLONE
1 active FDA Drug Master Files.
Request a quote for AGAMREE